Issue Date: January 14, 2013
Lonza Will Boost Conjugate Capability
The Swiss pharmaceutical chemicals firm Lonza plans to invest $15 million to expand antibody-drug conjugate (ADC) production capacity in Visp, Switzerland. Lonza calls itself a pioneer in the manufacturing of ADCs, which are now being tested against cancer in dozens of clinical trials. The firm says the project will double large-scale ADC capacity at the site when it is completed in the second quarter of 2014.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society